Persistent Or New Symptoms 1 Year After A Single High Dose Of Vitamin D3 In Patients With Moderate To Severe COVID-19

September 2022 in “ Frontiers in Nutrition ”

Alan Lins Fernandes, Lucas Peixoto Sales, Mayara D Santos, Valéria F. Caparbo, Igor H. Murai, Rosa Maria Rodrigues Pereira

vitamin D3 COVID-19 placebo randomized clinical trial post-hoc analysis quality of life QoL vitamin D COVID

TLDR High-dose vitamin D3 does not improve symptoms or quality of life in COVID-19 patients after one year.

This study investigated the effects of a single 200,000 IU dose of vitamin D3 on persistent or new symptoms and quality of life (QoL) in patients with moderate to severe COVID-19, 1 year post-hospitalization. Conducted as a post-hoc analysis of a multicenter, double-blind, placebo-controlled, randomized clinical trial in São Paulo, Brazil, 144 patients were followed up via telephone interviews at 6 and 12 months. The study found no significant differences between the vitamin D3 and placebo groups in terms of fever, cough, fatigue, myalgia, joint pain, and other symptoms, as well as QoL. The results do not support the use of high-dose vitamin D3 for managing persistent or new symptoms and QoL in these patients.

View this study on frontiersin.org →

Discuss this study in the Community →

Cited in this study

9 / 9 results

Trichodynia and Telogen Effluvium in COVID-19 Patients: Results of an International Expert Opinion Survey on Diagnosis and Management

research Trichodynia and Telogen Effluvium in COVID-19 Patients: Results of an International Expert Opinion Survey on Diagnosis and Management

39 citations, December 2021 in “JAAD International”

COVID-19 patients often experience hair loss and scalp pain, which may be related to the severity of their infection and treatment drugs.

research Time of Onset and Duration of Post-COVID-19 Acute Telogen Effluvium

32 citations, October 2021 in “Journal of The American Academy of Dermatology”

Hair loss from COVID-19 usually starts around 45 days after infection and lasts about 47.5 days.

research Role of Vitamin D in Hair Loss: A Short Review

14 citations, September 2021 in “Journal of Cosmetic Dermatology”

Low vitamin D levels are linked to various types of hair loss, but more research is needed before using it as a treatment.

research Post-COVID-19 Syndrome: Persistent Symptoms at the Post-Viral Stage of the Disease. A Systematic Review of Current Data

151 citations, May 2021 in “Frontiers in Medicine”

Many patients experience long-lasting symptoms like fatigue and pain after COVID-19, regardless of initial disease severity.

research Telogen Effluvium Associated with COVID-19 Infection

44 citations, January 2021 in “Dermatologic Therapy”

COVID-19 may cause hair loss due to infection stress or treatments.

research Efficacy of Oral Vitamin D3 Therapy in Patients Suffering from Diffuse Hair Loss (Telogen Effluvium)

6 citations, January 2021 in “Journal of Nutritional Science and Vitaminology”

Taking vitamin D3 pills helped improve hair growth in women with a certain type of hair loss.

research Telogen Effluvium: A Sequela of COVID-19

58 citations, November 2020 in “International Journal of Dermatology”

COVID-19 may cause a temporary hair loss condition called telogen effluvium in some patients after recovery.

research Telogen Effluvium Related to Post Severe SARS-CoV-2 Infection: Clinical Aspects and Our Management Experience

35 citations, November 2020 in “Dermatologic Therapy”

Severe COVID-19 may cause hair loss, and doctors recommend supplements and topical treatments to manage it.

research Telogen Effluvium: A Review of the Literature

40 citations, May 2020 in “Cureus”

The conclusion is that treatments for Telogen Effluvium exist, but standard treatment guidelines are needed.

1 / 1 results

research Persistent Or New Symptoms 1 Year After A Single High Dose Of Vitamin D3 In Patients With Moderate To Severe COVID-19

2 citations, September 2022 in “Frontiers in Nutrition”

High-dose vitamin D3 does not improve symptoms or quality of life in COVID-19 patients after one year.